Witjes - Figure 42
Other immunotherapy in high-risk patients
FIG. 42: What about mycobacterium cell wall particles? Obviously, this would be less toxic than live mycobacteria. Mycobacterium phlei cell wall-nucleic acid complex (MCNA) has been studied in 129 patients, and the result was that disease-free survival was >30% in the BCG-unresponsive patients vs 25% overall.[27,28]
References
Morales A, Herr H, Steinberg G, et al. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin. J Urol. 2015;193:1135−43 http://dx.doi.org/10.1016/j.juro.2014.09.109
Li R, Amrhein J, Cohen Z, et al. Efficacy of Mycobacterium phlei cell wall-nucleic acid complex (MCNA) in BCG-unresponsive patients. Bladder Cancer. 2017;3:65−71 https://doi.org/10.3233/BLC-160084
